.jpg "uniQure NV (QURE) Received its Third Buy in a Row")
After Cantor Fitzgerald and Chardan Capital gave uniQure NV (NASDAQ: QURE) a Buy rating last month, the company received another Buy, this time from H.C. Wainwright. Analyst Debjit Chattopadhyay maintained a Buy rating on uniQure NV today and set a price target of $48. The company’s shares closed yesterday at $28.10.
Chattopadhyay commented:
“Our $48 price target, is based on a 13-year DCF analysis that incorporates rNPV of two pipeline products, including: (1) Hemophilia B at a 70% POS driven by company’s clinical update as of September 23, 2018, vs. prior 65%; and (2) 5% POS. We anticipate Hemophilia B commercial launch during 2021 and model risk-adjusted peak sales of roughly $981M, upped from $820M previously, during 2028. We assume a launch price of $772.5K (durability >5 years), and at peak, we estimate about 775 patients in the U.S. and approximately 1,050 patients in the developed markets who would have received uniQure’s gene therapy, which represents a 50% of the overall commercial opportunity.”
According to TipRanks.com, Chattopadhyay has 0 stars on 0-5 star ranking scale with an average return of -3.4% and a 37.4% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Voyager Therapeutics Inc, and Mersana Therapeutics Inc.
Currently, the analyst consensus on uniQure NV is a Strong Buy with an average price target of $51.50, representing an 83.3% upside. In a report released yesterday, Chardan Capital also reiterated a Buy rating on the stock with a $50 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $43.23 and a one-year low of $13.71. Currently, uniQure NV has an average volume of 283.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington’s disease, glybera, and cardiovascular problems. The company was founded on January 9, 2012 and is headquartered in Amsterdam, the Netherlands.
Read More on QURE:
